Correlation Between Telomir Pharmaceuticals, and Oncolytics Biotech

Can any of the company-specific risk be diversified away by investing in both Telomir Pharmaceuticals, and Oncolytics Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Telomir Pharmaceuticals, and Oncolytics Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Telomir Pharmaceuticals, Common and Oncolytics Biotech, you can compare the effects of market volatilities on Telomir Pharmaceuticals, and Oncolytics Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Telomir Pharmaceuticals, with a short position of Oncolytics Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Telomir Pharmaceuticals, and Oncolytics Biotech.

Diversification Opportunities for Telomir Pharmaceuticals, and Oncolytics Biotech

-0.53

Correlation Coefficient

Telomir Pharmaceuticals,  Oncolytics Biotech

Excellent diversification

The 3 months correlation between Telomir and Oncolytics is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Telomir Pharmaceuticals, Commo and Oncolytics Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncolytics Biotech and Telomir Pharmaceuticals, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Telomir Pharmaceuticals, Common are associated (or correlated) with Oncolytics Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncolytics Biotech has no effect on the direction of Telomir Pharmaceuticals, i.e., Telomir Pharmaceuticals, and Oncolytics Biotech go up and down completely randomly.

Pair Corralation between Telomir Pharmaceuticals, and Oncolytics Biotech

Given the investment horizon of 90 days Telomir Pharmaceuticals, Common is expected to generate 2.44 times more return on investment than Oncolytics Biotech. However, Telomir Pharmaceuticals, is 2.44 times more volatile than Oncolytics Biotech. It trades about 0.02 of its potential returns per unit of risk. Oncolytics Biotech is currently generating about -0.01 per unit of risk. If you would invest  700.00  in Telomir Pharmaceuticals, Common on August 13, 2024 and sell it today you would lose (278.00) from holding Telomir Pharmaceuticals, Common or give up 39.71% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	78.14%
Values	Daily Returns

Telomir Pharmaceuticals, Commo  vs.  Oncolytics Biotech

Telomir Pharmaceuticals,

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Telomir Pharmaceuticals, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Telomir Pharmaceuticals, displayed solid returns over the last few months and may actually be approaching a breakup point.

Oncolytics Biotech

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Oncolytics Biotech are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Oncolytics Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Telomir Pharmaceuticals, and Oncolytics Biotech

The main advantage of trading using opposite Telomir Pharmaceuticals, and Oncolytics Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Telomir Pharmaceuticals, position performs unexpectedly, Oncolytics Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will offset losses from the drop in Oncolytics Biotech's long position.

The idea behind Telomir Pharmaceuticals, Common and Oncolytics Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.